Home/Filings/4/0001493152-22-035481
4//SEC Filing

Cashmere Karen A. 4

Accession 0001493152-22-035481

CIK 0001859007other

Filed

Dec 13, 7:00 PM ET

Accepted

Dec 14, 7:27 PM ET

Size

14.5 KB

Accession

0001493152-22-035481

Insider Transaction Report

Form 4
Period: 2022-12-12
Cashmere Karen A.
Chief Commercial Officer
Transactions
  • Award

    Stock Options (right to buy)

    2022-12-12+19,85419,854 total
    Exercise: $5.03Exp: 2027-10-30Common Stock (19,854 underlying)
  • Award

    Stock Options (right to buy)

    2022-12-12+9,9279,927 total
    Exercise: $5.03Exp: 2024-09-10Common Stock (9,927 underlying)
  • Award

    Stock Options (right to buy)

    2022-12-12+29,78129,781 total
    Exercise: $11.58Exp: 2029-04-02Common Stock (29,781 underlying)
  • Award

    Stock Options (right to buy)

    2022-12-12+21,84021,840 total
    Exercise: $16.36Exp: 2031-02-08Common Stock (21,840 underlying)
  • Award

    Stock Options (right to buy)

    2022-12-12+21,84021,840 total
    Exercise: $16.36Exp: 2032-01-28Common Stock (21,840 underlying)
Footnotes (5)
  • [F1]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on September 10, 2014.
  • [F2]100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
  • [F3]100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
  • [F4]The option vests in 3 equal annual installments commencing on February 8, 2022.
  • [F5]The option vests in 3 equal annual installments commencing on January 28, 2023.

Documents

1 file

Issuer

ZyVersa Therapeutics, Inc.

CIK 0001859007

Entity typeother

Related Parties

1
  • filerCIK 0001954546

Filing Metadata

Form type
4
Filed
Dec 13, 7:00 PM ET
Accepted
Dec 14, 7:27 PM ET
Size
14.5 KB